RPRXRoyalty Pharma plcLarge cap · $22.72B · FY ending 2025-12-31
$58.53+3.94% · 2026-07-16 · EOD
47/100 composite
A transparent blend of the four reads below — each opens into the tool it comes from. Not advice.Quality62
thin moat · ROIC 9%Value45
P/E 32.9 · 100% of 12-mo rangeMomentum78
golden · price above 200-daySmart Money2
selling · 1 funds · 0P/10S insidersBullish stackGolden crossAbove 200-day
vs S&P 500+36.8%
6-mo excess Trailing performance1M +7.8%
3M +20.2%
6M +45.0%
YTD +50.6%
1Y +60.3%
P/E vs its last 12 months (our price history): 19.6 low → 32.9 high
Current price sits at the 100th percentile of that window — near the top (richer). We only compare against the price history we own (no paid multi-year multiples — nothing invented).
No clear moat — ROIC 9%
Piotroski F4/9
fundamental strength Altman ZGrey
bankruptcy zone ROIC = NOPAT ÷ (debt + equity − cash), using an effective tax rate of 0%. Annual figures from SEC XBRL.
Dividend & capital return
Shareholder yield5.4%
dividends + buybacks Annual figures from SEC cash-flow statements. Shareholder yield = total cash returned ÷ market cap.
Net selling0P / 10S insiders · 1 funds hold · 0 Congress buys
Recent insidersHite Christopher · EVP & Chairman, PartneringSELL$7.3M
Urist Marshall · EVP, Research & InvestmentsSELL$508,454
Hite Christopher · EVP & Chairman, PartneringSELL$8.2M
Urist Marshall · EVP, Research & InvestmentsSELL$502,067
Fund holders (13F)Dorsey Asset Management (Pat Dorsey)$109.2M8.7% of book
Bhealth · 72/100
Self-fundingSelf-funding — profitable · generates cash
No red flags from its filings.
Educational tools — not financial advice. Fundamentals from SEC EDGAR (XBRL); prices are end-of-day (Databento). Scores are a transparent blend of the components shown, computed on our own data — a research aid, not a recommendation.